From clonal hematopoiesis to therapy-related myeloid neoplasms: The silent way of cancer progression

Carmelo Gurnari, Emiliano Fabiani, Giulia Falconi, Serena Travaglini, Tiziana Ottone, Antonio Cristiano, Maria Teresa Voso

Research output: Contribution to journalReview articlepeer-review


Clonal hematopoiesis (CH) has been recognized as a predisposing factor for the development of myeloid malignancies. Its detection has been reported at different frequencies across studies, based on the type of genome scanning approach used and the population studied, but the latest insights recognize its virtual ubiquitous presence in older individuals. The discovery of CH in recent years paved the way for a shift in the paradigm of our understanding of the biology of therapy-related myeloid malignancies (t-MNs). Indeed, we moved from the concept of a treatment-induced lesion to a model where CH precedes the commencement of any cancer-related treatment in patients who subsequently develop a t-MN. Invariant patterns of genes seem to contribute to the arising of t-MN cases, with differences regarding the type of treatment received. Here, we review the principal studies concerning CH, the relationship with myeloid progression and the mechanisms of secondary t-MN development.

Original languageEnglish
Article number128
Pages (from-to)1-14
Number of pages14
Issue number2
Publication statusPublished - Feb 2021


  • Clonal hematopoiesis
  • Myeloid progression
  • Therapy-related myeloid neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)


Dive into the research topics of 'From clonal hematopoiesis to therapy-related myeloid neoplasms: The silent way of cancer progression'. Together they form a unique fingerprint.

Cite this